CR9741A - Formas cristalinas de sal de calcio del acido (r-(r r)-2-(4-fluorofenil)-beta, delta dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino) carbonil-1h-pirrol-1-heptanoico (2:1) (divisional del exp. 7170) - Google Patents

Formas cristalinas de sal de calcio del acido (r-(r r)-2-(4-fluorofenil)-beta, delta dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino) carbonil-1h-pirrol-1-heptanoico (2:1) (divisional del exp. 7170)

Info

Publication number
CR9741A
CR9741A CR9741A CR9741A CR9741A CR 9741 A CR9741 A CR 9741A CR 9741 A CR9741 A CR 9741A CR 9741 A CR9741 A CR 9741A CR 9741 A CR9741 A CR 9741A
Authority
CR
Costa Rica
Prior art keywords
heptanoic
fluorophenyl
phenyl
acid salt
methylety
Prior art date
Application number
CR9741A
Other languages
English (en)
Inventor
Robert Byrn Stephen
Andrew Coates David
Sue Gushurst Karen
Grant Morrison Henry
Park Aeri
Ivanova Petinka
Jane Li Zheng
Francis Krzyzaniak Joseph
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23166039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9741(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CR9741A publication Critical patent/CR9741A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen formas cristalinas de la sal hemicalcica del acido [R-(R*,R*)] -2- (4-fluorofenil)-B-c-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino) carbonil]-1H-pirrol-1-heptanoico, denominadas Forma V, Forma VI, Forma Vii, Form VIII, Forma IX, Forma X, Forma XI, Forma XII, Forma XV, Forma XVI, Forma XVII, Forma XVIII y Forma XIX, que se caracterizan por sus patrones de difraccion de rayos X en polvo, RMN de estado solido y/o espectroscopia de Raman; asi como procedimientos para su preparacion y composiciones farmaceuticas de las mismas.
CR9741A 2001-06-29 2008-02-15 Formas cristalinas de sal de calcio del acido (r-(r r)-2-(4-fluorofenil)-beta, delta dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino) carbonil-1h-pirrol-1-heptanoico (2:1) (divisional del exp. 7170) CR9741A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30204901P 2001-06-29 2001-06-29

Publications (1)

Publication Number Publication Date
CR9741A true CR9741A (es) 2008-10-31

Family

ID=23166039

Family Applications (2)

Application Number Title Priority Date Filing Date
CR7170A CR7170A (es) 2001-06-29 2003-11-26 Formas cristalinas de sal de calcio del acido (r-(r r)-2-(4-fluorofenil)-beta, delta dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino) carbonil-1h-pirrol-1-heptanoico (2:1)
CR9741A CR9741A (es) 2001-06-29 2008-02-15 Formas cristalinas de sal de calcio del acido (r-(r r)-2-(4-fluorofenil)-beta, delta dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino) carbonil-1h-pirrol-1-heptanoico (2:1) (divisional del exp. 7170)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR7170A CR7170A (es) 2001-06-29 2003-11-26 Formas cristalinas de sal de calcio del acido (r-(r r)-2-(4-fluorofenil)-beta, delta dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino) carbonil-1h-pirrol-1-heptanoico (2:1)

Country Status (40)

Country Link
US (5) US6605729B1 (es)
EP (2) EP1423364B1 (es)
JP (2) JP3965155B2 (es)
KR (1) KR100609371B1 (es)
CN (2) CN1524073A (es)
AP (1) AP1571A (es)
AR (1) AR036118A1 (es)
AU (1) AU2002258092B2 (es)
BG (1) BG108393A (es)
BR (1) BR0210666A (es)
CA (1) CA2450111C (es)
CR (2) CR7170A (es)
CZ (1) CZ20033478A3 (es)
DO (1) DOP2002000413A (es)
EA (1) EA005317B1 (es)
EC (1) ECSP034928A (es)
EE (1) EE200300597A (es)
ES (1) ES2558565T3 (es)
GE (1) GEP20053546B (es)
HR (1) HRP20031039A2 (es)
HU (1) HUP0400381A2 (es)
IL (1) IL158790A0 (es)
MA (1) MA27044A1 (es)
MX (1) MXPA03010266A (es)
MY (1) MY122907A (es)
NO (1) NO326170B1 (es)
NZ (1) NZ529557A (es)
OA (1) OA12636A (es)
PA (1) PA8549501A1 (es)
PE (1) PE20030124A1 (es)
PL (1) PL367943A1 (es)
RS (1) RS100003A (es)
SK (1) SK16002003A3 (es)
SV (1) SV2003001144A (es)
TN (1) TNSN03147A1 (es)
TW (1) TWI319396B (es)
UA (1) UA74075C2 (es)
UY (1) UY27359A1 (es)
WO (1) WO2003004470A1 (es)
ZA (1) ZA200308731B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE69616808T2 (de) 1995-07-17 2002-05-29 Warner Lambert Co Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin)
US20040072138A1 (en) * 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20080275104A1 (en) * 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL155734A0 (en) * 2000-11-03 2003-11-23 Teve Pharmaceutical Ind Ltd Atorvastatin hemi-calcium form vii
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2623599A1 (en) * 2000-12-27 2002-07-04 Paul Adrian Van Der Schaaf Crystalline forms of atorvastatin
CN1524073A (zh) * 2001-06-29 2004-08-25 ����-�����ع�˾ ′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基）羰基-1H-吡咯-1-庚酸钙盐（2∶1）（阿托伐他汀）
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2003070702A1 (en) * 2002-02-15 2003-08-28 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
KR20090045419A (ko) * 2002-02-19 2009-05-07 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화
CA2491051A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
AU2003297594A1 (en) * 2002-11-28 2004-06-23 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
JP2007516294A (ja) * 2003-12-23 2007-06-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 炎症性の疾患または症状の予防および治療のための方法および組成物
WO2005090301A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
FI120344B (fi) 2004-03-17 2009-09-30 Ranbaxy Lab Ltd Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi
WO2005105738A2 (en) 2004-05-05 2005-11-10 Pfizer Products Inc. Salt forms of atorvastatin
CA2754932C (en) * 2004-07-20 2014-04-01 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
KR100881103B1 (ko) * 2004-09-28 2009-02-02 테바 파마슈티컬 인더스트리즈 리미티드 실질적으로 불순물을 함유하지 않는 아토르바스타틴 칼슘의형태를 제조하는 방법
MX2007004722A (es) * 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
US20090208539A1 (en) * 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
EP1688850A1 (en) 2005-02-07 2006-08-09 Sony Ericsson Mobile Communications AB Generic parser for electronic devices
US8506646B2 (en) * 2005-04-29 2013-08-13 Warsaw Orthopedic, Inc. Multi-purpose medical implant devices
US8092464B2 (en) * 2005-04-30 2012-01-10 Warsaw Orthopedic, Inc. Syringe devices and methods useful for delivering osteogenic material
WO2007057755A1 (en) 2005-11-21 2007-05-24 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium
EP1923057A1 (en) * 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Atorvastatin pharmaceutical formulation
CA2628666A1 (en) * 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Atorvastatin formulation
KR20100023059A (ko) * 2005-12-13 2010-03-03 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
KR100878140B1 (ko) 2007-01-29 2009-01-12 한미약품 주식회사 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
CA2679317A1 (en) * 2007-03-02 2008-09-12 Dong-A Pharm. Co., Ltd. Novel crystal forms of pyrrolylheptanoic acid derivatives
WO2008112887A1 (en) * 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
WO2008123953A1 (en) * 2007-04-02 2008-10-16 Merck & Co., Inc. Anti-hypercholesterolemic compound
DE102007052071A1 (de) 2007-10-30 2009-05-07 Stada Arzneimittel Ag Stabilisiertes Atorvastatin
CN102976996B (zh) * 2009-05-27 2015-08-19 峡江和美药业有限公司 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用
US9334266B2 (en) 2009-09-04 2016-05-10 The University Of Toledo Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
MX2013015272A (es) 2011-07-01 2014-04-14 Dsm Sinochem Pharm Nl Bv Cristales micronizados.
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
US10450957B2 (en) 2017-01-23 2019-10-22 United Technologies Corporation Gas turbine engine with heat pipe system
WO2020013330A1 (ja) * 2018-07-13 2020-01-16 協和発酵バイオ株式会社 ユーコミン酸の非溶媒和物結晶及びその製造方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
WO1994016693A1 (en) 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE69616808T2 (de) 1995-07-17 2002-05-29 Warner Lambert Co Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5998633A (en) 1996-07-29 1999-12-07 Warner-Lambert Company Process for the synthesis of protected esters of (S)-3,4-dihydroxybutyric acid
IN191236B (es) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
WO2001036384A1 (en) * 1999-11-17 2001-05-25 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
EP1237865B1 (en) * 1999-12-17 2005-11-16 Pfizer Science and Technology Ireland Limited A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt
AU780247B2 (en) * 1999-12-17 2005-03-10 Pfizer Science And Technology Ireland Limited A process for producing crystalline atorvastatin calcium
IL155734A0 (en) * 2000-11-03 2003-11-23 Teve Pharmaceutical Ind Ltd Atorvastatin hemi-calcium form vii
PT1341785E (pt) * 2000-11-16 2009-01-16 Teva Pharma Hidrólise de ésteres de ácidos r(r*,r*)-2-(4-fluorofenil)-beta,delta-di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico com hidróxido de cálcio
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2623599A1 (en) * 2000-12-27 2002-07-04 Paul Adrian Van Der Schaaf Crystalline forms of atorvastatin
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (es) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
GB0111077D0 (en) 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
CN1524073A (zh) * 2001-06-29 2004-08-25 ����-�����ع�˾ ′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基）羰基-1H-吡咯-1-庚酸钙盐（2∶1）（阿托伐他汀）
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
KR20100023059A (ko) * 2005-12-13 2010-03-03 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

Also Published As

Publication number Publication date
PL367943A1 (en) 2005-03-07
NO326170B1 (no) 2008-10-13
MA27044A1 (fr) 2004-12-20
NO20035675D0 (no) 2003-12-18
MY122907A (en) 2006-05-31
EA005317B1 (ru) 2004-12-30
AU2002258092B2 (en) 2007-05-17
AR036118A1 (es) 2004-08-11
WO2003004470A1 (en) 2003-01-16
EP3009423A2 (en) 2016-04-20
IL158790A0 (en) 2004-05-12
JP2005501032A (ja) 2005-01-13
CN101215253A (zh) 2008-07-09
EP1423364B1 (en) 2015-11-04
BR0210666A (pt) 2004-10-05
AU2002258092C1 (en) 2003-01-21
OA12636A (en) 2006-06-15
AP2003002936A0 (en) 2003-12-31
UA74075C2 (en) 2005-10-17
EP1423364A1 (en) 2004-06-02
US7144915B2 (en) 2006-12-05
RS100003A (en) 2007-02-05
BG108393A (bg) 2004-12-30
NZ529557A (en) 2005-05-27
ECSP034928A (es) 2004-02-26
JP2007182460A (ja) 2007-07-19
CA2450111C (en) 2006-02-07
HUP0400381A2 (hu) 2004-09-28
PE20030124A1 (es) 2003-02-12
US20080287521A1 (en) 2008-11-20
EE200300597A (et) 2004-02-16
JP3965155B2 (ja) 2007-08-29
DOP2002000413A (es) 2003-07-15
SV2003001144A (es) 2003-03-18
TWI319396B (en) 2010-01-11
UY27359A1 (es) 2003-04-30
EP3009423A3 (en) 2016-12-28
HRP20031039A2 (en) 2005-10-31
KR100609371B1 (ko) 2006-08-08
US20060241169A1 (en) 2006-10-26
AP1571A (en) 2006-02-10
US20080214651A1 (en) 2008-09-04
MXPA03010266A (es) 2004-03-10
CR7170A (es) 2004-02-23
CA2450111A1 (en) 2003-01-16
GEP20053546B (en) 2005-06-10
CZ20033478A3 (cs) 2004-10-13
CN1524073A (zh) 2004-08-25
SK16002003A3 (sk) 2004-12-01
US6605729B1 (en) 2003-08-12
EA200301243A1 (ru) 2004-06-24
ZA200308731B (en) 2004-11-10
PA8549501A1 (es) 2003-09-05
ES2558565T3 (es) 2016-02-05
KR20040014583A (ko) 2004-02-14
TNSN03147A1 (en) 2005-12-23
US20040054193A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
CR9741A (es) Formas cristalinas de sal de calcio del acido (r-(r r)-2-(4-fluorofenil)-beta, delta dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino) carbonil-1h-pirrol-1-heptanoico (2:1) (divisional del exp. 7170)
AR003458A1 (es) Forma cristalina de atorvastatina o hidrato de la misma y composicion farmaceutica que la comprende.
ID16158A (id) Garam kalsium asam [r-(r*,r*)]-2-(4-fluorofenil)-.beta,teta-dihidroksi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1h-pirol-1-heptanoat bentuk iii kristal (2:1)
BRPI0510713A (pt) formas de sal de ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-diidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)ca rbonil]-1h-pirrol-1- heptanóico
BR0211488A (pt) Formas cristalinas vi e vii de atorvastina cálcica
CA2508871A1 (en) Crystalline form f of atorvastatin hemi-calcium salt
AR058212A1 (es) Formas novedosas de acido (r-(r*, r* ))-2-(4-fluorofenil) - beta , delta- dihidroxi -5- (1- metiletil) -3-fenil-4- ( fenilamino) carbonil)-1h- pirrol -1- heptanoico magnesio
NO20060716L (no) Krystallinske former av `R-(Rx,)-2(4-fluorfenyl)-beta, delta-dihydroksy-5-(1metyletyl)-3-fenyl-4-`(fenylamino) karbonyl-1H-pyrrol-1-hetpansyre
CA2522899A1 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
TH61086A (th) รูปแบบผลึกของเกลือแคลเซียม (2
UY27608A1 (es) Formas cristalinas hidratadas de atorvastatina forma ii y forma iv.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)